Psoriasis diagnoses in Brazil's public health system grew 19.2% annually from 2019-2024, triple the pre-2019 rate, affecting skin, joints, nails and overall quality of life. Red plaques, nail changes, joint pain and itching are key symptoms; stress, infections, cold weather and certain medications trigger flare-ups in genetically predisposed individuals.
CartaCapital
· Jun 02, 2026
· health
· 4 min read
High
Sourcing: Verified
Psoríase: novos tratamentos transformam manejo da doença inflamatória crônica
Psoriasis impacts emotional wellbeing, sleep quality, self-esteem and productivity in millions of patients, with women experiencing delayed diagnoses compared to men.
◉
Health & Medicine
2697 related articles
Ozempic and GLP-1 drugs: how the weight-loss revolution works and what…
O GLOBO · 99% match
Eli Lilly's retatrutida shows 28% weight loss in trials, rivaling bari…
Poder360 · 90% match
GLP-1 drugs like Ozempic expand beyond weight loss into Alzheimer's, h…
Folha de S.Paulo · 90% match
Retatrutida achieves 30% weight loss in landmark obesity study
Veja Saúde · 90% match
Anvisa aprova remdesivir contra covid-19 e registra vacina de Oxford
Jornal de Brasília · 90% match
Related Coverage
Folha de S.Paulo · Aug 18
Projeto Quebrada Alimentada é eleito iniciativa de destaque em gastronomia pela Folha
O projeto Quebrada Alimentada, nascido no restaurante Mocotó durante a pandemia, foi eleito iniciativa de destaque pela …
Folha de S.Paulo · Aug 18 Cisne mantém reinado como melhor sal entre paulistanos pela quinta vezA marca Cisne vence pela quinta vez consecutiva a pesquisa Datafolha como melhor sal entre paulistanos, com 50% das menç…
UOL · Aug 17 Lucy Ramos revela que Globo consultou obstetra para cena de acidente na novelaA atriz Lucy Ramos revelou que a Globo consultou seu obstetra antes de gravar uma cena de acidente fatal enquanto ela es…
Estadão · Aug 17 Asma não impede atividade física; exercício regular ajuda no controle da doençaPesquisas confirmam que atividade física beneficia asmáticos, mas requer controle da doença e atenção a fatores ambienta…
Bias & Framing
⚖
Article presents medical information on psoriasis treatments with institutional sources; minimal apparent bias but relies heavily on pharmaceutical industry data and expert credentials from medical education company.
Bias Direction
center-right
Confidence
MED
Medical authority framing combined with pharmaceutical industry-friendly narrative. Article emphasizes new drug approval and market research data (Ipsos) showing disease growth, positioning pharmaceutical solutions as primary response to health challenge.
reacendeu o debate (reignited debate - suggests renewed urgency)
cenário também chama atenção (scenario also draws attention - implies concern)
crescimento expressivo (expressive/notable growth - emphasizes magnitude)
índices praticamente triplicaram (indices practically tripled - strong language emphasizing acceleration)
Patient voices and lived experiences with psoriasis
Cost-benefit analysis or affordability concerns for new medications
Alternative or complementary treatment approaches
Perspectives from public health officials on SUS capacity
Critical analysis of why diagnoses tripled (improved detection vs. actual disease increase)
Potential side effects or limitations of biologic treatments
Dermatologists without pharmaceutical company affiliations
Geopolitical Impact
🌎
Brazilian health article on psoriasis treatment advances; no geopolitical implications detected.
Escalation Risk
low
Confidence
HIGH
Economic Lens
📈
Brazil's psoriasis diagnoses tripled since 2019 with new biologic medications approved, expanding treatment options for 125M global patients and driving growth in pharmaceutical and healthcare sectors.
Market Signal
bullish
Confidence
HIGH
Pharmaceuticals & Biopharmaceuticals
Healthcare Services
Public Health (SUS)
Medical Devices
Dermatology Specialty Care
Patients gain access to improved biologic treatments with better outcomes, though affordability and SUS coverage expansion will determine accessibility for lower-income Brazilians. Increased diagnoses may reduce undiagnosed cases but increase treatment costs for households and public health system.
SUS budget pressures likely as treatment volume grows 25% annually; potential need for expanded pharmaceutical coverage policies. Anvisa approval acceleration suggests regulatory support for innovative therapies. Government may need to negotiate drug pricing and establish treatment guidelines for cost management.